David E. Coutant

Nanoparticles: Properties, applications and toxicities

A review on plant-based rutin extraction methods and its pharmacological activities

Evaluation on the adsorption capabilities of new chemically modified polymeric adsorbents with protoporphyrin IX

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

Characterisation and determination of fullerenes: A critical review

One‐Pot Functionalization of Graphene with Porphyrin through Cycloaddition Reactions

Current and prospective applications of metal ion–protein binding

Porphyrins in analytical chemistry. A review

Recent Advances in Insulin Therapy

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Compact Biocompatible Quantum Dots via RAFT-Mediated Synthesis of Imidazole-Based Copolymer Ligand

Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine ( L antus®) in patients with type 2 diabetes who were insulin‐naïve or previously treated with insulin glargine: a randomized, double‐blind controlled trial (the ELEMENT 2 study)

Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice

Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study

1107-P: Ultra Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs. Humalog (Lispro) in Patients with T1D

PO428 COMPARATIVE PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF LY2963016 INSULIN GLARGINE AND EU- AND US-APPROVED VERSIONS OF LANTUS® INSULIN GLARGINE IN HEALTHY SUBJECTS

Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies

PO427 COMPARATIVE PHARMACOKINETICS AND PHARMACODYNAMICS OF 2 INSULIN GLARGINE PRODUCTS, LY2963016 AND LANTUS® IN HEALTHY SUBJECTS AT 2 DOSE LEVELS

96 - Ultra Rapid Lispro (URLi) Lowers Postprandial Glucose (PPG) and More Closely Matches Normal Physiological Glucose Response Compared to Other Rapid Insulin Analogs

Immobilized Porphyrins as Versatile Stationary Phases in Liquid Chromatography

1100-P: Ultra Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs. Humalog (Lispro) in Patients with T2D

Selective separation of fullerenes on hydroxyphenyl-triphenylporphyrin–silica stationary phases